Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Puma Biotechnology (PBYI) over the last 7 years, with Q3 2025 value amounting to $26000.0.

  • Puma Biotechnology's Capital Expenditures rose 3000.0% to $26000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $123000.0, marking a year-over-year increase of 4470.59%. This contributed to the annual value of $56000.0 for FY2024, which is 6000.0% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Capital Expenditures is $26000.0, which was up 3000.0% from $20000.0 recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Capital Expenditures peaked at $7.0 million during Q3 2022, and registered a low of -$7.0 million during Q4 2022.
  • Its 4-year average for Capital Expenditures is $23500.0, with a median of $23000.0 in 2024.
  • Within the past 5 years, the most significant YoY rise in Puma Biotechnology's Capital Expenditures was 10064.29% (2023), while the steepest drop was 9961.43% (2023).
  • Puma Biotechnology's Capital Expenditures (Quarter) stood at -$7.0 million in 2022, then soared by 100.64% to $45000.0 in 2023, then plummeted by 64.44% to $16000.0 in 2024, then soared by 62.5% to $26000.0 in 2025.
  • Its Capital Expenditures was $26000.0 in Q3 2025, compared to $20000.0 in Q2 2025 and $61000.0 in Q1 2025.